FR2910324B1 - Nouveau medicament pour le traitement d'un cancer gastrique - Google Patents

Nouveau medicament pour le traitement d'un cancer gastrique

Info

Publication number
FR2910324B1
FR2910324B1 FR0655835A FR0655835A FR2910324B1 FR 2910324 B1 FR2910324 B1 FR 2910324B1 FR 0655835 A FR0655835 A FR 0655835A FR 0655835 A FR0655835 A FR 0655835A FR 2910324 B1 FR2910324 B1 FR 2910324B1
Authority
FR
France
Prior art keywords
treatment
gastric cancer
new medicine
medicine
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR0655835A
Other languages
English (en)
Other versions
FR2910324A1 (fr
Inventor
Pierre Miossec
Ling Toh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomerieux SA
Hospices Civils de Lyon HCL
Original Assignee
Biomerieux SA
Hospices Civils de Lyon HCL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomerieux SA, Hospices Civils de Lyon HCL filed Critical Biomerieux SA
Priority to FR0655835A priority Critical patent/FR2910324B1/fr
Priority to EP07871986A priority patent/EP2091611A2/fr
Priority to PCT/FR2007/052575 priority patent/WO2008087329A2/fr
Priority to US12/312,774 priority patent/US20100055108A1/en
Publication of FR2910324A1 publication Critical patent/FR2910324A1/fr
Application granted granted Critical
Publication of FR2910324B1 publication Critical patent/FR2910324B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR0655835A 2006-12-21 2006-12-21 Nouveau medicament pour le traitement d'un cancer gastrique Active FR2910324B1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
FR0655835A FR2910324B1 (fr) 2006-12-21 2006-12-21 Nouveau medicament pour le traitement d'un cancer gastrique
EP07871986A EP2091611A2 (fr) 2006-12-21 2007-12-20 Nouveau médicament pour le traitement d'un cancer gastrique
PCT/FR2007/052575 WO2008087329A2 (fr) 2006-12-21 2007-12-20 Nouveau médicament pour le traitement d'un cancer gastrique
US12/312,774 US20100055108A1 (en) 2006-12-21 2007-12-20 Drug for treating gastric cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0655835A FR2910324B1 (fr) 2006-12-21 2006-12-21 Nouveau medicament pour le traitement d'un cancer gastrique

Publications (2)

Publication Number Publication Date
FR2910324A1 FR2910324A1 (fr) 2008-06-27
FR2910324B1 true FR2910324B1 (fr) 2009-03-06

Family

ID=38222271

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0655835A Active FR2910324B1 (fr) 2006-12-21 2006-12-21 Nouveau medicament pour le traitement d'un cancer gastrique

Country Status (4)

Country Link
US (1) US20100055108A1 (fr)
EP (1) EP2091611A2 (fr)
FR (1) FR2910324B1 (fr)
WO (1) WO2008087329A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
TW201117824A (en) * 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
DK3295957T3 (da) 2010-01-15 2019-10-14 Kirin Amgen Inc Anti il-17ra-antistofformulering og terapeutiske regimener til behandling af psoriasis
EP2569335B1 (fr) * 2010-05-14 2018-08-22 Orega Biotech Méthodes de traitement et/ou de prévention de troubles de prolifération cellulaire à l'aide d'antagonistes de il-17
MX339762B (es) 2011-09-28 2016-05-27 Univ Autonoma Del Estado De Morelos Metalopeptidos inmunomoduladores (immp) y composiciones que los contienen.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT817847E (pt) * 1995-03-23 2005-02-28 Immunex Corp Receptor de il-17
GB0425569D0 (en) * 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
MX2007009811A (es) * 2005-02-14 2007-09-07 Wyeth Corp Anticuerpos para interleucina-17f y otros antagonistas de la senalizacion de il 17f, y sus usos.

Also Published As

Publication number Publication date
FR2910324A1 (fr) 2008-06-27
WO2008087329A2 (fr) 2008-07-24
WO2008087329A3 (fr) 2008-11-27
US20100055108A1 (en) 2010-03-04
EP2091611A2 (fr) 2009-08-26

Similar Documents

Publication Publication Date Title
FR2925339B1 (fr) Medicament pour le traitement du cancer du pancreas
FR22C1034I2 (fr) Rapports de médicament fixes pour le traitement des cancers hématopoïétiques et des troubles prolifératifs
EP2101757A4 (fr) Composé pour le traitement ou la prévention de maladies en relation avec la prostate et compositions pharmaceutiques de système d'administration par le colon contenant ce composé
EP1985302A4 (fr) Médicament pour le traitement de tumeurs et son utilisation
EP2151435A4 (fr) Composition pharmaceutique pour le traitement de la maladie d'alzheimer
EP2041317A4 (fr) Procédés et compositions à base de micro-arn pour le diagnostic et le traitement de maladies apparentées au cancer du colon
IL192299A0 (en) Use of nitrooxyderivative of drug for the treatment of muscular dystrophies
BRPI1006115A2 (pt) "agentes indutores de apoptose para o tratamento de câncer e doenças autoimunes".
FR2908999B1 (fr) Nouveau medicament destine a l'inhibition, la prevention ou le traitement de la polyarthrite rhumatoide.
WO2011026125A3 (fr) Compositions pharmaceutiques à rétention gastrique permettant une libération immédiate et prolongée d'acétaminophène
EP1749532A4 (fr) Médicament pour la guérison ou le traitement d'une blessure
FR2915102B1 (fr) Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer
ZA201200944B (en) Pharmaceutical compositions for the treatment of cancer and other diseases or disorders
EP2137175A4 (fr) Nouveau composé à base de phénanthrènequinone et composition pharmaceutique contenant ce dernier utilisé pour le traitement ou la prévention du syndrome métabolique impliquant des maladies
ZA200805761B (en) Pharmaceutical composition for the treatment of nail disease
FR2956313B1 (fr) Appareil pour l'administration d'une substance visqueuse pendant une operation chirurgicale.
HK1132451A1 (en) Use of ck2 inhibitor for the treatment and chemosensibilization of refractory tumors to anticancer drugs
FR2910324B1 (fr) Nouveau medicament pour le traitement d'un cancer gastrique
FR2918282B1 (fr) Medicament pour le traitement de la maladie de parkinson
FR2952305B1 (fr) Medicament inhalable a base de xenon pour traiter ou pour prevenir les dyskinesies
EP2231148A4 (fr) Composition pharmaceutique utilisée dans le traitement et la prévention d'une maladie cardiaque
FR2906468B1 (fr) Utilisation de composes de la famille des avermectines pour le traitement de desordres dermatologiques
GB0715790D0 (en) Drug combination for the treatment of sialorrhoea
IT1392547B1 (it) Dispositivo per l'infusione di farmaci
EP2222295A4 (fr) Composition pharmaceutique utilisée dans le traitement et la prévention de maladies rénales

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 11

PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16

PLFP Fee payment

Year of fee payment: 17